Bristol-Myers Squibb Company [BMY] moved up 0.52: Why It’s Important

Bristol-Myers Squibb Company [NYSE: BMY] stock went on an upward path that rose over 0.52% on Monday, amounting to a one-week price increase of more than 2.22%. The company report on November 3, 2022 that Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


– $25 million equity investment from Bristol Myers Squibb at $18.25 per share –.

– Term loan facility from Hercules Capital provides up to $125 million –.

Over the last 12 months, BMY stock rose by 33.20%. The one-year Bristol-Myers Squibb Company stock forecast points to a potential upside of 2.09. The average equity rating for BMY stock is currently 2.20, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $167.87 billion, with 2.13 billion shares outstanding and 2.12 billion shares in the current float. Compared to the average trading volume of 9.49M shares, BMY stock reached a trading volume of 7659727 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Bristol-Myers Squibb Company [BMY]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BMY shares is $80.88 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BMY stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Guggenheim have made an estimate for Bristol-Myers Squibb Company shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on October 10, 2022. While these analysts kept the previous recommendation, Berenberg dropped their target price from $82 to $76. The new note on the price target was released on September 14, 2022, representing the official price target for Bristol-Myers Squibb Company stock.

The Average True Range (ATR) for Bristol-Myers Squibb Company is set at 1.58, with the Price to Sales ratio for BMY stock in the period of the last 12 months amounting to 3.59. The Price to Book ratio for the last quarter was 5.17, with the Price to Cash per share for the same quarter was set at 4.26. Price to Free Cash Flow for BMY in the course of the last twelve months was 20.63 with Quick ratio for the last quarter at 1.30.

BMY Stock Performance Analysis:

Bristol-Myers Squibb Company [BMY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.22. With this latest performance, BMY shares gained by 13.62% in over the last four-week period, additionally plugging by 3.83% over the last 6 months – not to mention a rise of 33.20% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BMY stock in for the last two-week period is set at 75.58, with the RSI for the last a single of trading hit 83.05, and the three-weeks RSI is set at 69.54 for Bristol-Myers Squibb Company [BMY]. The present Moving Average for the last 50 days of trading for this stock 71.59, while it was recorded at 78.32 for the last single week of trading, and 72.67 for the last 200 days.

Insight into Bristol-Myers Squibb Company Fundamentals:

Bristol-Myers Squibb Company’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.40.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BMY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bristol-Myers Squibb Company go to 4.35%.

Bristol-Myers Squibb Company [BMY] Insider Position Details

There are presently around $131,253 million, or 79.90% of BMY stock, in the hands of institutional investors. The top three institutional holders of BMY stocks are: VANGUARD GROUP INC with ownership of 196,828,094, which is approximately -0.837% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 170,645,262 shares of the stock with an approximate value of $13.51 billion in BMY stocks shares; and JPMORGAN CHASE & CO, currently with $7.74 billion in BMY stock with ownership of nearly 4.129% of the company’s market capitalization.

1,119 institutional holders increased their position in Bristol-Myers Squibb Company [NYSE:BMY] by around 116,616,285 shares. Additionally, 1,153 investors decreased positions by around 76,404,158 shares, while 356 investors held positions by with 1,464,422,720 shares. The mentioned changes placed institutional holdings at 1,657,443,163 shares, according to the latest SEC report filing. BMY stock had 130 new institutional investments in for a total of 8,022,558 shares, while 113 institutional investors sold positions of 7,385,277 shares during the same period.


Please enter your comment!
Please enter your name here